Understand your health. Know what to ask.
GLP-1 expectations at a higher starting weight: pounds, percentages and health
Why the same number of pounds can mean different changes at different starting weights, and how to read treatment results more clearly.
2 sources · NIHRead · 2 min →
GLP-1 weight loss and muscle: what the numbers mean
Weight loss can include fat and lean mass. Body-composition studies and strength measures answer different questions about muscle health.
4 sources · NIH, PubMed / PMCRead · 2 min →
GLP-1 medicines and alcohol: what the evidence says
Alcohol questions depend on the exact medicine, other prescriptions and health history. Early craving research does not establish a safe drinking amount.
4 sources · NIH, PubMed / PMCRead · 2 min →
When a GLP-1 feels less effective: hunger and weight trends
A change in appetite or a pause in weight loss needs a broader review. Treatment response includes weight trends, tolerability and health goals.
5 sources · NIH, PubMed / PMCRead · 2 min →
PCOS, irregular periods and GLP-1 medicines: different goals of care
How GLP-1 weight management fits alongside PCOS assessment, glucose testing and pregnancy planning.
2 sources · NIHRead · 2 min →
Before starting tirzepatide: the decisions that matter
Understand the treatment goal, medical review, side effects, reproductive considerations and follow-up before starting tirzepatide.
2 sources · FDA, NIHRead · 2 min →
A semaglutide plateau: what to review before switching
A pause in weight change is a reason to review the treatment, not an automatic reason to switch to tirzepatide.
3 sources · NIHRead · 2 min →
Weight changes and fatigue: looking at both together
Weight and energy can change for several reasons. A useful evaluation considers sleep, symptoms, medicines, and selected tests together.
3 sources · NIHRead · 2 min →
Your first GLP-1 consultation: what gets reviewed
A first GLP-1 visit covers health history, treatment goals, medication safety, product details and follow-up. A prescription is only one possible outcome.
4 sources · FDA, NIHRead · 2 min →
GLP-1 maintenance and “microdosing”: what the labels establish
Maintaining weight loss is a treatment goal. “Microdosing” does not identify an FDA-approved regimen or guarantee fewer side effects.
4 sources · FDA, NIHRead · 2 min →
Semaglutide vs. tirzepatide: what single and dual action mean
Semaglutide targets GLP-1 receptors; tirzepatide targets GIP and GLP-1 receptors. How that difference fits into a treatment comparison.
3 sources · FDA, NIHRead · 2 min →
Insulin resistance: which tests help assess glucose?
Insulin resistance and prediabetes are related but different. A1c, fasting glucose, and glucose-tolerance testing help assess the glucose picture.
2 sources · NIHRead · 2 min →